Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor

  • Angela Sardaro Department of Interdisciplinary Medicine, Section of Diagnostic Imaging and Radiotherapy, University Aldo Moro, Bari, Italy.
  • Lilia Bardoscia | liliabardoscia@gmail.com Department of Interdisciplinary Medicine, Section of Diagnostic Imaging and Radiotherapy, University Aldo Moro, Bari, Italy.
  • Maria Fonte Petruzzelli Department of Interdisciplinary Medicine, Section of Diagnostic Imaging and Radiotherapy, University Aldo Moro, Bari, Italy.
  • Maurizio Portaluri Department of Radiotherapy, A. Perrino Hospital, Brindisi; Clinical Physiology Institute, National Research Council (IFC-CNR), Pisa-Lecce, Italy.

Abstract

Epithelioid hemangioendothelioma is a rare vascular tumor, described for the first time in 1975 by Dail and Liebow as an aggressive bronchoalveolar cell carcinoma. The etiology is still a dilemma. Studies about suggestive hypothesis are ongoing. Most of the times it affects lung, liver and bones, although this kind of tumor may involve the head and neck area, breast, lymph nodes, mediastinum, brain and meninges, the spine, skin, abdomen and many other sites. Because of its heterogeneous presentation, as it represents less than 1% of all the vascular tumors, it is often misdiagnosed and not suitably treated, leading to a poor prognosis in some cases. Over 50-76% of the patients are asymptomatic. A small number of them complains respiratory symptoms. Bone metastases might cause pathological fractures or spine compression, if they arise in vertebrae. Imaging is necessary to determine morphological data, the involvement of surrounding tissues, and potentially the cleavage plan. It is important to recognize the expression of vascular markers (Fli-1 and CD31 are endothelial-specific markers), and the microscopic evidence of vascular differentiation to make a correct diagnosis, as many pulmonary diseases show multiple nodular lesions. Because of its rarity, there is no standard for treatment. We focused on radiotherapy as a good therapeutic option: despite the poor prognosis, evidence is in favor of radiotherapy which offers local pain control with good tolerance and better quality of life at least at a one-year follow-up in most of cases. Further studies are needed to establish the standard radiation dose to be used for locoregional control of such a complex and extremely rare disease.

Downloads

Download data is not yet available.
Published
2014-10-13
Section
Reviews
Keywords:
bone metastases, endothelial markers, epithelioid hemangioendothelioma, radiation therapy, vascular tumor, pulmonary nodules.
Statistics
Abstract views: 19440

PDF: 4013
HTML: 2469
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Sardaro, A., Bardoscia, L., Petruzzelli, M., & Portaluri, M. (2014). Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor. Oncology Reviews, 8(2). https://doi.org/10.4081/oncol.2014.259

Most read articles by the same author(s)